Background: Equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy (eNAD/EDM) is an inherited neurodegenerative disorder associated with a vitamin E deficiency within the first year of life. Vitamin E consists of 8 isoforms metabolized by the CYP4F2 enzyme. No antemortem diagnostic test currently exists for eNAD/EDM.
Hypothesis/objectives: Based on the association of α-tocopherol deficiency with the development of eNAD/EDM, we hypothesized that the rate of α-tocopherol, but not γ-tocopherol or tocotrienol metabolism, would be increased in eNAD/EDM-affected horses.
Animals: Vitamin E metabolism: Proof of concept (POC) study; eNAD/EDM-affected (n = 5) and control (n = 6) horses. Validation study: eNAD/EDM-affected Quarter Horses (QHs; n = 6), cervical vertebral compressive myelopathy affected (n = 6) horses and control (n = 29) horses. CYP4F2 expression and copy number: eNAD/EDM-affected (n = 12) and age- and sex-matched control (n = 11-12) horses.
Methods: The rates of α-tocopherol/tocotrienol and γ-tocopherol/tocotrienol metabolism were assessed in equine serum (POC and validation) and urine (POC only) using liquid chromatography tandem mass spectrometry (LC-MS/MS). Quantitative reverse-transcriptase PCR (qRT-PCR) and droplet digital (dd)-PCR were used to assay expression and genomic copy number of a CYP4F2 equine ortholog.
Results: Metabolic rate of α-tocopherol was increased in eNAD/EDM horses (POC,P < .0001; validation, P = .03), with no difference in the metabolic rate of γ-tocopherol. Horses with eNAD/EDM had increased expression of the CYP4F2 equine orthologue (P = .02) but no differences in copy number.
Conclusions And Clinical Importance: Increased α-tocopherol metabolism in eNAD/EDM-affected QHs provides novel insight into alterations in vitamin E processing in eNAD/EDM and highlights the need for high-dose supplementation to prevent the clinical phenotype in genetically susceptible horses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478026 | PMC |
| http://dx.doi.org/10.1111/jvim.16233 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A fresh look at the SarcoFluor antibody test for the detection of specific antibodies to Sarcocystis neurona for the diagnosis of equine protozoal myeloencephalitis.
Vet Parasitol
August 2024
Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California Davis, Tupper Hall 2108, One Shields Avenue, Davis, CA 95616, USA.
Equine protozoal myeloencephalitis (EPM) is a challenging disease to diagnose in horses with neurological signs. To optimize contemporary diagnostic testing, including the use of serum:CSF antibody ratios, the SarcoFluor antibody test for Sarcocystis neurona requires revalidation. The SarcoFluor, a previously validated immunofluorescent antibody test (IFAT) for the detection of antibodies specific to S.
View Article and Find Full Text PDFCurrent insights into equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy.
Vet J
June 2024
Center for Equine Health, School of Veterinary Medicine, University of California, Davis, CA, USA; Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, CA, USA. Electronic address:
Article Synopsis
- * There are no pre-death tests available for diagnosing eNAD/EDM; definitive diagnosis requires postmortem examination of the brain and spinal cord, while research is ongoing to find reliable antemortem indicators.
- * Prevention strategies include ensuring pregnant mares and foals have access to pasture and potentially supplementing their diets with high doses of vitamin E, but monitoring is necessary to avoid overdosing, which can lead to blood clotting issues.
Clinicopathological and pedigree investigation of a novel spinocerebellar neurological disease in juvenile Quarter Horses in North America.
J Vet Intern Med
May 2024
Department of Population Health and Reproduction, School of Veterinary Medicine, University of California Davis, Davis, California, USA.
Background: In 2020, a novel neurologic disease was observed in juvenile Quarter Horses (QHs) in North America. It was unknown if this was an aberrant manifestation of another previously described neurological disorder in foals, such as equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy (eNAD/EDM).
Hypothesis/objectives: To describe the clinical findings, outcomes, and postmortem changes with Equine Juvenile Spinocerebellar Ataxia (EJSCA), differentiate the disease from other similar neurological disorders, and determine a mode of inheritance.
Equine neuroaxonal dystrophy/degenerative myeloencephalopathy in Gypsy Vanner horses.
J Vet Intern Med
May 2024
Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, California 95616, USA.
Article Synopsis
- eNAD/EDM is a neurodegenerative disease affecting young horses, particularly those deficient in vitamin E, and has not been observed in Gypsy Vanner horses until now.
- A study evaluated 26 Gypsy Vanners for clinical symptoms, vitamin E levels before and after supplementation, and confirmed the presence of eNAD/EDM in some horses through necropsy.
- Results showed a high percentage of low pre-supplementation vitamin E levels and only half achieved normal vitamin E levels after supplementation, suggesting a possible genetic predisposition in Gypsy Vanners and the need for careful vitamin E monitoring in young horses.
Measurement of 8-hydroxy-2'-deoxyguanosine in serum and cerebrospinal fluid of horses with neuroaxonal degeneration and other causes of proprioceptive ataxia.
J Vet Intern Med
March 2024
Department of Clinical Studies, New Bolton Center, University of Pennsylvania School of Veterinary Medicine, Kennett Square, Pennsylvania, USA.
Background: Eight-hydroxy-2'-deoxyguanosine (8-OHdG), a biomarker of oxidative damage evaluated in human neurodegenerative disease, has potential to correlate with postmortem diagnosis of neuroaxonal dystrophy/degenerative myeloencephalopathy (NAD/DM) in horses.
Hypothesis: We hypothesized that 8-OHdG will be higher in CSF and serum from NAD/DM horses compared with horses with other neurologic diseases (CVSM, EPM) and a control group of neurologically normal horses. We also hypothesized that 8-OHdG will be higher in CSF compared with serum from NAD/DM horses.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!